<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799015</url>
  </required_header>
  <id_info>
    <org_study_id>2020-12625</org_study_id>
    <nct_id>NCT04799015</nct_id>
  </id_info>
  <brief_title>Dexamethasone for Post Traumatic Headache</brief_title>
  <official_title>A Randomized Study of Dexamethasone as Adjuvant Therapy for Acute Post-traumatic Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study of intravenous metoclopramide + intravenous dexamethasone versus&#xD;
      intravenous metoclopramide for patients with acute post-traumatic headache.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate or Severe headache after Emergency Department discharge</measure>
    <time_frame>48 hours</time_frame>
    <description>Rating headache moderate or severe on a scale of severe, moderate, mild, or none</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained headache relief</measure>
    <time_frame>48 hours</time_frame>
    <description>Achieving a headache intensity of mild or none in the emergency department without use of rescue medication and maintaining that level for 48 hours without use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post concussive symptom scale</measure>
    <time_frame>48 hours and 7 days after emergency department discharge</time_frame>
    <description>The Sport Concussion Assessment Tool (SCAT) Post Concussion Symptom Scale (PCSS). On this validated instrument, patients rate 22 concussive symptoms on a 0 to 6 scale, with 6 signifying more severe pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Post-Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 10mg IV + metoclopramide 10mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV + metoclopramide 10mg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 10mg IV</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide 10mg</intervention_name>
    <description>Metoclopramide 10mg IV</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Included patients will be adults who meet International Classification of Headache&#xD;
             Disorders criteria for acute post-traumatic headache. These are as follows:&#xD;
&#xD;
          -  Traumatic injury to the head has occurred&#xD;
&#xD;
          -  Headache has developed within 7 days of injury to the head&#xD;
&#xD;
          -  Headache is not better accounted for by another diagnosis (eg, migraine or&#xD;
             tension-type headache)&#xD;
&#xD;
          -  The headache must be rated as moderate or severe in intensity at the time of initial&#xD;
             evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if more than ten days have elapsed since the head trauma, if&#xD;
             the headache has already been treated with an anti-dopaminergic medication, or for&#xD;
             medication allergies or contra-indications including pheochromocytoma, seizure&#xD;
             disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection&#xD;
             transplant medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Friedman, MD</last_name>
    <phone>718-920-6626</phone>
    <email>befriedm@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Friedman, MD</last_name>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

